{"id":300,"date":"2023-03-23T22:00:00","date_gmt":"2023-03-23T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=300"},"modified":"2025-09-13T13:38:05","modified_gmt":"2025-09-13T13:38:05","slug":"china-bd-2023-highlightll-and-biohaven-enters-a-970-million-usd-license-on-dual-tyk2-jak1-inhibitor-tll-041-bhv-8000","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2023\/300.html","title":{"rendered":"[China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2\/JAK1 Inhibitor\u00a0TLL-041 (BHV-8000)"},"content":{"rendered":"\n<p>Announced Date: 2023-03-22 March 22, 2023)<\/p>\n\n\n\n<p>Asset Name: TLL-041 (BHV-8000)<\/p>\n\n\n\n<p>Licensor (Seller): Hangzhou Highlightll Pharmaceutica (China)<\/p>\n\n\n\n<p>Licensee (Buyer): Biohaven Therapeutics (US)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: Small Molecule<\/p>\n\n\n\n<p>Asset Target: Dual TYK2\/JAK1 Inhibitor\u00a0<\/p>\n\n\n\n<p>Potential Indication: brain disorders<\/p>\n\n\n\n<p>Current until deal: \u00a0phase I<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Biohaven acquired global rights, excluding\u00a0China regions, for the development of\u00a0an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1)  BHV-8000 (previously TLL-041)  for the treatment of brain disorders. <br><\/p>\n\n\n\n<p>Biohaven and Highlightll will coordinate clinical development across global regions.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail:<\/p>\n\n\n\n<p>Highlightll will receive\u00a0<\/p>\n\n\n\n<p>$10 million in upfront cash and\u00a0$10 million\u00a0in BHVN equity, <\/p>\n\n\n\n<p>Development and commercial milestone payments of up to\u00a0$950 million.<\/p>\n\n\n\n<p>Tiered royalty payments ranging from mid-single digit to lower teens percentages.\u00a0\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/ir.biohaven.com\/news-releases\/news-release-details\/biohaven-acquires-exclusive-license-oral-brain-penetrant-dual\">Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2\/JAK1 Inhibitor for Immune-Mediated Brain Disorders | Biohaven, Ltd.<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Hangzhou Highlightll Pharmaceutical, \u676d\u5dde\u9ad8\u5149\u5236\u836f<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2023-03-22 March 22, 2023) Asset Name: TLL-041 (BHV-8000) Licensor (Seller): Hangzhou Highlightll Pharmaceutica (China) &hellip; <a title=\"[China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2\/JAK1 Inhibitor\u00a0TLL-041 (BHV-8000)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2023\/300.html\"><span class=\"screen-reader-text\">[China BD 2023] Highlightll and Biohaven enters a 970 million USD License on Dual TYK2\/JAK1 Inhibitor\u00a0TLL-041 (BHV-8000)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-300","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=300"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/300\/revisions"}],"predecessor-version":[{"id":301,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/300\/revisions\/301"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}